The role of diffusion-weighted MR imaging in the diagnosis of bladder urothelial cancer

doi:10.3877/cma.j.issn.1674-3253.2017.06.011

Abstract

Abstract:

Objective

To evaluate the value of diffusion-weighted MR imaging in diagnosis of urothelial cancer.

Methods

From June 2015 to December 2016, 72 consecutive patients with suspicious bladder lesions were accessed in our hospital. According to the results of pathological examination, the patients were divided into two groups: benign lesions group (n=23) and urothelial cancer group (n=49). The apparent diffusion coefficient (ADC) values of all patients was analyzed. The receiver operating characteristic (ROC) curves were generated by plotting the sensitivity versus specificity. Area under the cures was calculated for ADC assay.

Results

There was significant difference in ADC values between benign lesions group and urothelial cancer group [(1.86±0.40)×10^-3mm²/s vs (0.93±0.11) ×10^-3mm²/s, P<0.01]. Area under the ROC curves of ADC values were 0.705. The specificity and sensitivity of ADC values were 82.9% and 87.2% respectively at the optimum cutoff value (1.32×10^-3 ) mm²/s.

Conclusions

ADC value could provide an objective and reliable biomarker for the early diagnosis of bladder urothelial cancer.

Key words: Bladder urothelial cancer, Diagnosis, Diffusion-weighted MR imaging

Zhanao Meng, Yadi He, Taolin Xia, Zihuan Luo, Xiaobo Chen, Xin Gao, Liaoyuan Li. The role of diffusion-weighted MR imaging in the diagnosis of bladder urothelial cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2017, 11(06): 404-406.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2017.06.011

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2017/V11/I06/404

Figures/Tables 2

References 15

[1]	He YD, Luo ZH, Yang M, et al. Prospective validation of DACH2 as a novel biomarker for prediction of metastasis and prognosis in muscle-invasive urothelial carcinoma of the bladder[J]. Biochem Biophys Res Commun, 2015, 459(3): 416-423.
[2]	Pickles MD, Gibbs P, Lowry M, et al, Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer[J]. Magn Reson Imaging, 2006, 24(7): 843-847.
[3]	Moffat BA, Chenevert TL, Lawrence TS, et al, Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinica brain tumor response[J]. Proc Natl Acad Sci USA, 102(15): 5524-5529.
[4]	Palou J, Algaba F, Vera I, et al. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin[J]. Eur Urol, 2009, 56(5): 829-836.
[5]	van den Bosch S, Alfred Witjes J. Long-term Cancer-specific Survival in Patients with High-risk, Non-muscle-invasive Bladder Cancer and Tumour Progression: a systematic review[J]. Eur Urol, 2011, 60(3): 493-500.
[6]	Cancer GN. Comprehensive molecular characterization of urothelial bladder carcinoma[J]. Nature, 2014, 507(7492): 315-322.
[7]	李辽源，吴杰英，刘绍远，等. 膀胱尿路上皮癌组织中DACH2的表达及临床意义[J/CD]. 中华腔镜泌尿外科杂志:电子版, 2016, 10(6): 45-48.
[8]	Li LY, Yang M, Zhang HB, et al. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma[J]. BJU Int, 2008, 102(5): 566-571.
[9]	Matsuki M, Inada Y, Tatsugami F, et al. Diffusion-weighted Mr imaging for urinary bladder carcinoma: initial results[J]. Eur Radiol, 2007, 17(1): 201-204.
[10]	Qayyum A. Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications[J]. Radiographics, 2009, 29(6): 1797-1810.
[11]	Panebianco V, Barchetti F, De Haas RJ, et al. Improving staging in bladder cancer: the increasing role of multiparametric magnetic resonance imaging[J]. Eur Urol Focus, 2016, 2(2): 113-121.
[12]	Bagheri MH, Ahlman MA, Lindenberg L, et al. Advances in medical imaging for the diagnosis and management of common genitourinary cancers[J]. Urol Oncol, 2017, 35(7): 473-491.
[13]	Lim KS, Tan CH. Diffusion-weighted MRI of adult male pelvic cancers[J]. Clin Radiol, 2012, 67(9): 899-908.
[14]	Nakamura Y, Yoshida S, Tanaka H, et al. Potential utility of Diffusion-Weighted magnetic resonance imaging in diagnosis of residual bladder cancer before second transurethral resection[J]. Urol Int, 2017, 98(3): 298-303.
[15]	Lee M, Shin SJ, Oh YT, et al. Non-contrast magnetic resonance imaging for bladder cancer: fused high b value diffusion-weighted imaging and T2-weighted imaging helps evaluate depth of invasion[J]. Eur Radiol, 2017, 27(9): 3752-3758.

组别	例数	性别（例）		年龄（岁）	ADC值（×10^-3mm²/s）
组别	例数	男	女	年龄（岁）	ADC值（×10^-3mm²/s）
膀胱良性疾病组	23	13	10	52±7	1.86±0.40
膀胱尿路上皮癌组	49	27	22	55±7	0.93±0.11
统计值	?	χ²=0.013		t=1.36	t=18.24
P值	?	0.91		0.18	<0.01

组别	例数	性别（例）		年龄（岁）	ADC值（×10^-3mm²/s）
组别	例数	男	女	年龄（岁）	ADC值（×10^-3mm²/s）
膀胱良性疾病组	23	13	10	52±7	1.86±0.40
膀胱尿路上皮癌组	49	27	22	55±7	0.93±0.11
统计值	?	χ²=0.013		t=1.36	t=18.24
P值	?	0.91		0.18	<0.01

Cut-off值（10^-3 mm²/s）	敏感性（%）	特异性（%）	阳性预测值（%）	阴性预测值（%）
1.26	75.0	57.3	65.8	73.4
1.13	80.0	54.1	61.2	74.9
1.04	85.0	50.6	60.4	78.5
0.96	90.0	49.2	59.7	81.3
0.85	95.0	44.7	57.3	82.6
0.71	100.0	36.5	52.6	100.0

Cut-off值（10^-3 mm²/s）	敏感性（%）	特异性（%）	阳性预测值（%）	阴性预测值（%）
1.26	75.0	57.3	65.8	73.4
1.13	80.0	54.1	61.2	74.9
1.04	85.0	50.6	60.4	78.5
0.96	90.0	49.2	59.7	81.3
0.85	95.0	44.7	57.3	82.6
0.71	100.0	36.5	52.6	100.0

Please choose a citation manager

Content to export